-
![SeanKhozin_hi-rez]( "Ten Years In, Project Data Sphere Is Snowballing")
Ten Years In, Project Data Sphere Is Snowballing6/21/2024Project Data Sphere, an open access data sharing initiative, is expanding into closed access preclinical research and developing AI models that can benefit drug developers.
-
![Womens health feature]( "Partnering To Address 'Huge' Opportunities In Women's Health")
Partnering To Address 'Huge' Opportunities In Women's Health6/14/2024Nonprofit research foundations can offer scientific expertise and support for biopharmaceutical drug development and clinical programs, helping companies improve new and existing drugs for women.
-
![Otsuka cover_Oct 2016]( "Where Are They Now? Otsuka")
Where Are They Now? Otsuka5/30/2024Otsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.
-
![James Porter_Nuvalent]( "Drug Discovery And Development, Powered By Physician Intelligence")
Drug Discovery And Development, Powered By Physician Intelligence5/15/2024For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.
-
![Armon_Sharei_450x300]( "Where Are They Now? SQZ Biotech")
Where Are They Now? SQZ Biotech5/1/2024SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
![Lax Bhat_Reviva]( "Reviva Pharma's Novel Funding Approach In Schizophrenia")
Reviva Pharma's Novel Funding Approach In Schizophrenia4/25/2024Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.
-
![Nicolas Poirier_OSE Immunotherapeutics]( "Companies To Watch: OSE Immunotherapeutics")
Companies To Watch: OSE Immunotherapeutics4/22/2024OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
![Yaacov Michlin]( "A View From The Co-Chair Of Israel's Biopharma Industry Trade Organization")
A View From The Co-Chair Of Israel's Biopharma Industry Trade Organization3/28/2024Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.
-
![John Valliant_Fusion Pharma]( "Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals")
Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals3/22/2024AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.